Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Unknown 2Recruiting 2

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Sarcoma 4Gynecologic 1

Conditions

Sarcoma 4Osteosarcoma 2Neoplasms 2Chondrosarcoma 2Uterine Neoplasms 1Sarcoma, Synovial 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Histiocytoma, Malignant Fibrous 1Dermatofibrosarcoma 1Adenoviridae Infections 1

Interventions

Doxorubicin 142Ifosfamide 85Radiotherapy 82Cyclophosphamide 72Gemcitabine 63Filgrastim 54pembrolizumab 43pazopanib 40Etoposide 39Docetaxel 39Vincristine 37Trabectedin 37Cisplatin 35Nivolumab 32Magnetic Resonance Spectroscopy 26Irinotecan 26Carboplatin 25Temozolomide 23Surgical Procedures, Operative 23Radiation 22Ipilimumab 22Bevacizumab 20Blood Specimen Collection 19Granulocyte Colony-Stimulating Factor 18Biopsy 18eribulin 17Sirolimus 17Mesna 17Melphalan 17Dactinomycin 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Sarcoma × Immune Checkpoint Inhibitors × Sarcoma × Clear all
NCT04995003 2026-01-22

HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma

Baylor College of Medicine

Phase 1 Recruiting
25 enrolled
Sarcoma

Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial

NCT04673942 2024-10-26

BETA-PRIME

EpicentRx, Inc.

Phase 2 Recruiting
140 enrolled
Sarcoma

Adenoviridae Infections, Chondrosarcoma, Neoplasms, Sarcoma

NCT04606108 2020-10-28

Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of High-risk Soft Tissue Sarcoma

Sun Yat-sen University

Phase 2 Unknown
62 enrolled
Sarcoma

Sarcoma

NCT04239443 2020-01-27

Clinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and Uterine Cancer

Hunan Cancer Hospital

Phase 2 Unknown
120 enrolled
GynecologicSarcoma

Sarcoma, Uterine Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡